SCHEMBL493511

SCHEMBL493511

c1nc(-c2ccc3c(c2)OCO3)no1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.49
LMNA P02545 1/20 0.49
NPC1 O15118 8/20 0.48
RAB9A P51151 8/20 0.48
SMN1; SMN2 Q16637 6/20 0.48
KMT2A Q03164 4/20 0.48
MEN1 O00255 3/20 0.48
PKM P14618 2/20 0.48
MAPT P10636 7/20 0.47
POLB P06746 3/20 0.47
TP53 P04637 2/20 0.46
GAA P10253 1/20 0.46
ESR2 Q92731 1/20 0.46
ALDH1A1 P00352 5/20 0.45
NISCH Q9Y2I1 1/20 0.44
CLK4 Q9HAZ1 4/20 0.44
USP2 O75604 3/20 0.44
CYP1A2 P05177 2/20 0.44
CYP3A4 P08684 2/20 0.44
CYP2D6 P10635 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7614422 0.75 CLK4 (0.49) KDM4ELMNANPC1RAB9ASMN1; SMN2
SCHEMBL15436312 0.72 NPC1 (0.82) KDM4ELMNANPC1RAB9ASMN1; SMN2
SCHEMBL22162812 0.71 CA12 (0.58) KDM4ELMNANPC1RAB9ASMN1; SMN2
SCHEMBL10498406 0.70 ADORA2A (0.50) KDM4ELMNANPC1RAB9ASMN1; SMN2
SCHEMBL10498506 0.70 ADORA1 (0.52) KDM4ELMNANPC1RAB9ASMN1; SMN2
SCHEMBL25440225 0.70 RAB9A (0.65) KDM4ELMNANPC1RAB9ASMN1; SMN2
SCHEMBL25440335 0.70 KDM4E (0.55) KDM4ELMNANPC1RAB9ASMN1; SMN2
SCHEMBL12864670 0.70 ALDH1A1 (0.58) KDM4ELMNANPC1RAB9ASMN1; SMN2
SCHEMBL2529766 0.69 TDP1 (0.48) KDM4ELMNASMN1; SMN2KMT2AMEN1
SCHEMBL4031773 0.69 KDM4E (0.53) KDM4ELMNANPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250179008-A1 ANTIBACTERIAL AGENTS TAXIS PHARMACEUTICALS, INC. (US) 2025-06-05 US disclosed
US-20220274968-A1 Oxazole And Oxadiazole Derivatives Useful As Agonists Of Free Fatty Acid Receptor 1 GBIOTECH S.À.R.L. (CH) 2022-09-01 US disclosed
US-8106055-B2 Substituted amide compounds GRUENENTHAL GMBH (DE) 2012-01-31 US disclosed
US-20080306084-A1 Substituted Amide Compounds GRUENENTHAL GMBH (DE) 2008-12-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080306084-A1 Substituted Amide Compounds OPRK1, NAA50, ACMSD KDM4E 2178/4885LMNA 2485/4885NPC1 519/4885
US-20250179008-A1 ANTIBACTERIAL AGENTS ALK, ROS1, NOX1 KDM4E 2407/4885LMNA 1817/4885NPC1 1400/4885
US-20220274968-A1 Oxazole And Oxadiazole Derivatives Useful As Agonists Of Free Fatty Acid Receptor 1 FFAR2, FFAR1, FFAR3 KDM4E 3951/4885LMNA 4289/4885NPC1 2356/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.